Thus, comprehensive decomposition of the molecular features of triple negative cancers and comparison with that of HER2 positive cancers may lead to the identification of the unique path to the malignancy of triple negative breast cancer cells as compared with the other subtypes and, ultimately, the identification of novel approaches for the effective control of such cancers. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.